AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$BOLT

Nemec Sarah sold $26K of BOLT

Nemec Sarah (Senior VP, Finance and PAO) sold 7,842 shares of Bolt Biotherapeutics, Inc. (BOLT) at an average of $3.32 ($3.24–$3.77) across 3 trades over 2026-09-16 to 2026-09-18.

Original reporting
SEC EDGAR · Nemec Sarah
Published Sep 21, 2026, 10:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BOLT
Neutral
high confidence
Mentioned
$BOLT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLTNeutralLow
01

Why it matters

The sale is modest and unlikely to affect BOLT's stock price in the short term.

02

Market read

Limited relevance; primarily of interest to insiders and compliance monitors.

03

What to watch

Potential upcoming clinical data releases could change sentiment regardless of this sale.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 disclosures provide the first public record of insider transactions.

Company-level read

Ticker impact

$BOLTNeutralHigh confidence
Context

Senior VP of Finance sold 7,842 shares for $26K in a Form 4 filing.

Expected impact

No material price movement expected.

Evidence & confidence

The transaction amount is small relative to market cap and does not alter ownership significantly.

Market effects

Sector

None; biotech sector unchanged.

Regional

No regional effect.

Global

Insignificant.

Counterpoint

What could challenge this read

Even small insider sells can precede larger moves; monitor for further disposals.

Key entities

  • Company
    Bolt Biotherapeutics, Inc.

    Biotech firm developing therapies.

  • Insider
    Sarah Nemec

    Senior VP, Finance and PAO at Bolt Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BOLT insider trading history →

Related articles

$BOLTHighAI 8/10

Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary de

SEC EDGAR 8-K
$BOLTHigh

Bolt Biotherapeutics, Inc. (BOLT): Completion of Acquisition or Disposition of Assets

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications • Transactions position the company to advance Prana’s pipeline of next-generation, half-lif

SEC EDGAR 8-K